Compare ELTX & FOSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | FOSL |
|---|---|---|
| Founded | 2011 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.3M | 339.5M |
| IPO Year | 2014 | 1994 |
| Metric | ELTX | FOSL |
|---|---|---|
| Price | $2.00 | $4.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $18.00 | $7.00 |
| AVG Volume (30 Days) | 315.6K | ★ 698.5K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.29 | 25.26 |
| EPS | N/A | ★ N/A |
| Revenue | $2,301,000.00 | ★ $1,004,406,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $1.70 |
| 52 Week High | $16.00 | $6.25 |
| Indicator | ELTX | FOSL |
|---|---|---|
| Relative Strength Index (RSI) | 20.92 | 41.10 |
| Support Level | N/A | $3.83 |
| Resistance Level | $3.32 | $5.01 |
| Average True Range (ATR) | 0.13 | 0.26 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 0.93 | 30.00 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Fossil Group Inc is a design, innovation, and distribution company in consumer fashion accessories, offering products such as watches, jewelry, handbags, small leather goods, belts, and sunglasses. It designs, develops, markets, and distributes products under its owned brands FOSSIL, SKAGEN, MICHELE, RELIC, and ZODIAC. It operates through Americas, Europe, and Asia segments, each including sales to wholesale and distributor customers, as well as Company-owned retail stores and e-commerce activities based on the location of the selling entity. The Americas segment contributes the majority of revenue and includes sales across Canada, Latin America, and the United States, while the Europe and Asia segments cover their respective regions. Each segment provides similar products and services.